Animal models for HIV/AIDS research
T Hatziioannou, DT Evans - Nature Reviews Microbiology, 2012 - nature.com
The AIDS pandemic continues to present us with unique scientific and public health
challenges. Although the development of effective antiretroviral therapy has been a major …
challenges. Although the development of effective antiretroviral therapy has been a major …
HIV/AIDS: in search of an animal model
AIDS is among the most devastating diseases of our time, claiming the lives of
approximately 3 million people per year. The primary cause of AIDS, human …
approximately 3 million people per year. The primary cause of AIDS, human …
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
H Li, S Wang, R Kong, W Ding… - Proceedings of the …, 2016 - National Acad Sciences
Most simian–human immunodeficiency viruses (SHIVs) bearing envelope (Env)
glycoproteins from primary HIV-1 strains fail to infect rhesus macaques (RMs). We …
glycoproteins from primary HIV-1 strains fail to infect rhesus macaques (RMs). We …
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
T Bradley, J Pollara, S Santra, N Vandergrift… - Nature …, 2017 - nature.com
Abstract The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and
recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine …
recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine …
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
DC Hsu, A Schuetz, R Imerbsin, D Silsorn… - PLoS …, 2021 - journals.plos.org
Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb)
administration previously delayed viral rebound and induced SHIV remission. We evaluated …
administration previously delayed viral rebound and induced SHIV remission. We evaluated …
Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates
Chimeric antigen receptor (CAR) T cells targeting CD19+ hematologic malignancies have
rapidly emerged as a promising, novel therapy. In contrast, results from the few CAR T-cell …
rapidly emerged as a promising, novel therapy. In contrast, results from the few CAR T-cell …
Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization
LE McCoy, AF Quigley, NM Strokappe… - Journal of Experimental …, 2012 - rupress.org
Llamas (Lama glama) naturally produce heavy chain–only antibodies (Abs) in addition to
conventional Abs. The variable regions (VHH) in these heavy chain–only Abs demonstrate …
conventional Abs. The variable regions (VHH) in these heavy chain–only Abs demonstrate …
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge
K Om, D Paquin-Proulx, M Montero, K Peachman… - PLoS …, 2020 - journals.plos.org
To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a
prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env …
prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env …
Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
B cell follicles in secondary lymphoid tissues represent an immune privileged sanctuary for
AIDS viruses, in part because cytotoxic CD8+ T cells are mostly excluded from entering the …
AIDS viruses, in part because cytotoxic CD8+ T cells are mostly excluded from entering the …
A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques
The rising global HIV-1 burden urgently requires vaccines capable of providing
heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming …
heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming …